论文部分内容阅读
目的:探讨微小RNA-141(miR-141)在卵巢癌患者组织和血清中的表达情况并初步探讨其作为肿瘤标记物早期诊断上皮性卵巢癌的可行性。方法:采用实时荧光定量逆转录聚合酶链反应(real-time RT-PCR)检测16例上皮性卵巢癌患者和4例正常人卵巢组织及血清标本中miR-141的表达;检测4例良性卵巢肿瘤血清中miR-141的表达。结果:miR-141在卵巢癌患者组织中相对表达量分别为(72.846±76.671)显著高于正常人(2.869±3.201)(P<0.05);miR-141在卵巢癌患者血清中相对表达量(31.581±52.885)显著高于良性卵巢肿瘤患者(0.668±1.196)和正常人(1.690±1.697)(P<0.05),后两组间表达无差异(P>0.05);miR-141表达随卵巢癌临床分期的进展呈上升趋势(P<0.01),在无淋巴结转移组明显高于有淋巴结转移组(P<0.05),与组织分级和CA125的升高无关(P>0.05)。在组织中miR-141表达水平与上皮性卵巢癌临床病理特征均未见明显差异(P>0.05)。结论:miR-141可能在上皮性卵巢癌的发生发展中发挥癌基因的作用;miR-141用于检测上皮性卵巢癌敏感性和特异度较高,有望成为上皮性卵巢癌早期诊断的新指标。
OBJECTIVE: To investigate the expression of microRNA-141 (miR-141) in the tissue and serum of patients with ovarian cancer and to investigate the feasibility of early detection of epithelial ovarian cancer as a tumor marker. Methods: The expression of miR-141 in 16 cases of epithelial ovarian cancer and 4 normal human ovarian tissues and serum samples were detected by real-time RT-PCR. Four cases of benign ovarian Expression of miR-141 in tumor serum. Results: The relative expression of miR-141 in ovarian cancer tissue was 72.846 ± 76.671 (2.869 ± 3.201), respectively (P <0.05). The relative expression of miR-141 in serum of patients with ovarian cancer ( 31.581 ± 52.885) were significantly higher than those in benign ovarian tumors (0.668 ± 1.196) and normal subjects (1.690 ± 1.697) (P <0.05), but no difference was found between the two groups (P> 0.05) The progress of clinical staging showed an upward trend (P <0.01), which was significantly higher in patients with lymph node metastasis than those with lymph node metastasis (P <0.05), but not with histological grade and CA125 elevation (P> 0.05). There was no significant difference in the expression of miR-141 between the tissue and the clinicopathological features of epithelial ovarian cancer (P> 0.05). Conclusion: miR-141 may play an oncogene role in the development and progression of epithelial ovarian cancer. MiR-141 is highly sensitive and specific for the detection of epithelial ovarian cancer and may be a new indicator of early diagnosis of epithelial ovarian cancer .